Mesudipine, a dihydropyridine analog, is a calcium antagonistic drug (slow channel blocker). It blocks electrical activity in smooth muscle cells and Purkinje fibers.

Metanixin is an analgesic and anti-inflammatory agent.

Lintopride is a benzamide, eliciting prokinetic properties on the upper gut in several animal models. Lintopride increases gastric emptying, stimulates antral and duodenal motility and accelerates intestinal transit in animals. In canines it also increases lower oesophageal sphincter (LOS) pressure and reinforces peristaltic waves after wet swallowing, indicating a stimulatory action which could potentially be greater than that of metoclopramide. The 5HT-4 agonist lintopride increases LOS basal pressure and the amplitude of peristaltic waves of the oesophagus following a single intravenous dose in healthy subjects. The action of lintopride on LOS basal pressure and oesophageal peristaltic waves could be beneficial in patients with gastro-oesophageal reflux disease.

Thiacetarsamide is a drug containing trivalent arsenic. In the USA it was used for the treatment of Heartworm Infection in dogs and cats under tradename Caparsolate, however, it was discontinued because of the availability of safer alternatives. The mechanism of action for thiacetarsamide is modulation of glucose uptake and metabolism; inhibition of glutathione reductase, and alteration of the structure and function of the surface of the intestinal epithelium of the parasites.

Lomeguatrib is a O6-methylguanine-DNA-methyl-transferase inhibitor which was developed by AstraZeneca for the treatment of cancer. It was tested in phase I and II of clinical trials for the treatment of colorectal cancer, melanoma and other solid tumors.

Tifemoxone is a tetrahydrooxazine derivative patented by Delalande S.A. as an analgesic, spasmolytic, antidepressive agent. In preclinical studies, Tifemoxone caused thyreotoxicity, hairlessness and increased in water consumption and diuresis and in addition it had a strong hepatotoxic effect especially in the dog.

Timirdine (also known as EGY-4201) is an iminothiazolidine derivative patented by EGIS Gyogyszergyar as an antidepressant. In the behavioral despair model and in antagonizing the effect of tetrabenazine, Timirdine efficacy was considerably higher than that of several tricyclic and second-generation antidepressant drugs. Timirdine was also active in inhibiting the hypothermic effect of apomorphine. It potentiated the lethal effect of yohimbine, the hypermotility provoked by L-dopa, and the stereotypy induced by D-amphetamine. In contrast to amitriptyline and nomifensine, Timirdine showed neither sedative nor stimulant actions on spontaneous and conditioned behavior.

Thymotrinan (also known as RGH-0205) is a protected synthetic tripeptide patented by Hungarian multinational pharmaceutical and biotechnology company Gedeon Richter Plc. (Richter, Gedeon, Vegyeszeti Gyar Rt) as an immunomodulating agent. Thymotrinan is the shortest thymopoietin fragment, that induces differentiation of CD90 cytotoxic T cell in the thymus. In preclinical models Thymotrinan is shown to exert similar immunomodulatory activities to thymopoietin affecting both humoral and cellular responses. In chronic 28-days i.v. toxicity studies in dogs no adverse reaction has been found. The low toxicity of Thymotrinan is probably attributable to their short half-life.

Tizabrin is the antithrombotic, fibrinolytic agent. Tizabrin (CP-2129) stimulates fibrinolysis after intravenous administration in human volunteers due to an increase in tissue plasminogen activator (t-PA) activity. Tizabrin has no intrinsic fibrinolytic activity in vitro.